Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Lorlatinib is a novel, third-generation, small-molecule dual ALK/ROS1 tyrosine kinase inhibitor developed by Pfizer Inc., USA.Lorlatinib Side Effects Requiring Immediate Medical At···【more】
Article source：Captain MedicineRelease date：2026-03-05Recommended：22
In September 2018, Lorlatinib was first approved for marketing in Japan, followed by approval from the U.S. Food and Drug Administration (FDA) in November of the same year, and the···【more】
Article source：Captain MedicineRelease date：2026-03-05Recommended：32
On October 12, 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Encorafenib in combination with Binimetinib for the treatment of adult pati···【more】
Article source：Captain MedicineRelease date：2026-03-05Recommended：21
In June 2018, the U.S. Food and Drug Administration (FDA) approved Binimetinib for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations. In Octob···【more】
Article source：Captain MedicineRelease date：2026-03-05Recommended：20
Whether long-term administration of stiripentol is required depends on the control of the condition and the physician’s evaluation. This medication is mainly used for refractory ep···【more】
Article source：Captain MedicineRelease date：2026-03-04Recommended：30
Whether the side effects of stiripentol diminish over time varies between individuals and depends on the specific type of adverse reaction. Some patients may experience short-term ···【more】
Article source：Captain MedicineRelease date：2026-03-04Recommended：29
Stiripentol is an adjuvant drug commonly used for drug-resistant epilepsy (such as Dravet syndrome). Its common side effects include drowsiness, loss of appetite, fatigue, weight c···【more】
Article source：Captain MedicineRelease date：2026-03-04Recommended：30
The price of stiripentol is affected by factors such as specification, dosage, and purchase channels, usually ranging from several hundred to several thousand yuan. The actual sell···【more】
Article source：Captain MedicineRelease date：2026-03-04Recommended：27
Sabril ( Lucius Pharmaceuticals vigabatrin) is an antiepileptic drug primarily used for the treatment of infantile spasms and refractory epilepsy. It demonstrates significant effic···【more】
Article source：Captain MedicineRelease date：2026-03-03Recommended：21
Sabril (vigabatrin) is an antiepileptic drug used for the treatment of refractory epilepsy, especially infantile spasms. Its side effects require close monitoring under the guidanc···【more】
Article source：Captain MedicineRelease date：2026-03-03Recommended：25
The price of Sabril (Vigabatrin) varies significantly depending on specifications, import channels, and other factors. It generally ranges from 300 to 2000 RMB per box. The exact c···【more】
Article source：Captain MedicineRelease date：2026-03-03Recommended：25
Fidaxomicin is an antibiotic used to treat Clostridium difficile infections. Its common side effects include gastrointestinal reactions such as abdominal pain, nausea, and vomiting···【more】
Article source：Captain MedicineRelease date：2026-02-28Recommended：24
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：1592025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3992024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：1532025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：1712025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：1532025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：1872025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：1672025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：1622025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
